Amundi
BMRN icon

Amundi’s BioMarin Pharmaceuticals BMRN Stock Holding History

Amundi’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Sell
188,536
-9,047
-5% -$527K ﹤0.01% 872
2025
Q4 		$11.7M Sell
197,583
-515,304
-72% -$28.1M ﹤0.01% 915
2025
Q3 		$39.6M Buy
712,887
+145,272
+26% +$8.31M 0.01% 611
2025
Q2 		$32.5M Buy
567,615
+161,936
+40% +$9.54M 0.01% 632
2025
Q1 		$27.4M Buy
405,679
+6,441
+2% +$433K 0.01% 656
2024
Q4 		$27.3M Buy
399,238
+88,247
+28% +$5.91M 0.01% 666
2024
Q3 		$21.4M Sell
310,991
-36,006
-10% -$3.01M 0.01% 703
2024
Q2 		$28.1M Sell
346,997
-97,123
-22% -$8.09M 0.01% 641
2024
Q1 		$40M Buy
444,120
+68,910
+18% +$6.17M 0.02% 567
2023
Q4 		$36.1M Sell
375,210
-397,780
-51% -$35.2M 0.02% 598
2023
Q3 		$66.7M Buy
772,990
+341,737
+79% +$30.4M 0.03% 441
2023
Q2 		$37M Sell
431,253
-736,068
-63% -$69.3M 0.02% 579
2023
Q1 		$113M Sell
1,167,321
-506,372
-30% -$52.5M 0.06% 326
2022
Q4 		$186M Sell
1,673,693
-70,739
-4% -$6.64M 0.1% 227
2022
Q3 		$156M Buy
1,744,432
+1,448,878
+490% +$129M 0.09% 241
2022
Q2 		$25.6M Buy
295,554
+34,039
+13% +$2.71M 0.02% 576
2022
Q1 		$21.8M Buy
261,515
+111,623
+74% +$9.34M 0.01% 638
2021
Q4 		$13.2M Buy
149,892
+3,984
+3% +$329K 0.01% 776
2021
Q3 		$11.3M Buy
145,908
+7,933
+6% +$626K 0.01% 815
2021
Q2 		$11.5M Buy
+137,975
New +$10.9M 0.01% 801

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's BMRN Position: Q1 2026 in Review

Amundi reduced its BioMarin Pharmaceuticals (BMRN) stake by 4.6% in Q1 2026, selling an estimated $527K and leaving 188,536 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Amundi first reported a position in BMRN in Q2 2021 and has held it in 20 quarters since. The position peaked at $186M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Amundi held 188,536 shares of BioMarin Pharmaceuticals worth $10.7M as of Q1 2026.
  • Amundi sold 9,047 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $527K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #872 holding.
  • Amundi first reported a position in BioMarin Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Amundi's BioMarin Pharmaceuticals position peaked at $186M in Q4 2022.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.